Tarsus Pharmaceuticals, Inc. Balance Sheet
TARS / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
Tarsus Pharmaceuticals, Inc. had $562M in total assets and $343M in shareholders' equity as of FY2025. Total debt was $72M against $184M in cash, resulting in a $111M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $183.6M | $94.8M | $224.9M | $71.7M | $171.3M | $168.1M | $58.0M | - |
| Accounts Receivable | $85.1M | $46.8M | $16.6M | - | - | - | - | - |
| Inventory | $4.4M | $2.6M | $3.1M | - | - | - | - | - |
| Current Assets | $522.8M | $356.7M | $256.1M | $225.4M | $176.0M | $170.7M | $58.0M | - |
| PP&E (Net) | $11.7M | $2.3M | $1.5M | $957.0K | $755.0K | $548.0K | $154.0K | - |
| Total Assets | $562.2M | $377.0M | $265.5M | $227.9M | $178.9M | $172.0M | $58.3M | - |
| Current Liabilities | $135.7M | $80.6M | $36.9M | $15.4M | $11.5M | $5.4M | $819.0K | - |
| Total Debt | $72.4M | $71.8M | $29.8M | $19.4M | $0 | - | - | - |
| Shareholders' Equity | $343.4M | $224.5M | $197.0M | $166.7M | $166.7M | $166.0M | -$6.0M | -$1.4M |